Lipophilic Cannabinoid-Terpenoid Solution for Animal Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cannabinoid-based treatments for animals lack standardization, leading to inconsistent and potentially toxic formulations, with a lack of clinical studies and acceptance within the veterinary medical community, particularly due to the toxicity of THC in dogs and the misunderstanding of CBD products for pets.
Innovation Solution
A lipophilic cannabinoid-terpenoid solution (CTS) comprising specific ratios of CBD, THC, and terpenes, administered via a controlled delivery system, providing a standardized and safe medication for treating various conditions in animals, including epilepsy, anxiety, and pain, while also collecting clinical data for dosage monitoring.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If CBD products for pets are provided only for oral administration, then the products are easy to manufacture and administer, but the absorption is inconsistent and poor
Solution Approach 1:
The patent introduces a lipophilic carrier as an intermediary substance that facilitates the absorption of cannabinoids through the blood-brain barrier. This carrier acts as a mediator between the cannabinoid and the target tissue, enabling consistent and reliable absorption while maintaining ease of oral administration. The lipophilic carrier solubilizes the cannabinoid and transports it across biological membranes, resolving the contradiction between ease of administration and absorption consistency.
2Reliability
If THC is used in cannabinoid products for animals, then the medicinal effects are enhanced, but the toxicity to animals especially dogs increases
Solution Approach 1:
The patent applies parameter changes by precisely controlling the concentration ratio of THC to CBD in the cannabinoid product. By adjusting this parameter (the ratio of THC to CBD), the formulation achieves optimal medicinal effectiveness while staying below toxic thresholds for animals. The lipophilic carrier further modifies the pharmacokinetic parameters, enabling enhanced efficacy at safer doses. This parameter optimization resolves the contradiction between medicinal effectiveness and toxicity.
3Reliability
If standardized cannabinoid-terpenoid solution is developed, then consistent and safe medication can be provided, but the development cost and complexity increase
Solution Approach 1:
The patent employs composite materials by combining multiple components in a standardized ratio: cannabinoids (CBD and THC), terpenoids, and a lipophilic carrier. This composite formulation achieves consistent and safe medication through the synergistic interaction of its components. The standardized composition of the composite material ensures reproducibility and reliability across batches, while the integrated nature of the composite reduces overall formulation complexity compared to separate preparations.
4Reliability
If clinical studies are conducted to provide reliable data, then acceptance within the medical establishment increases, but the time and resources required increase
Solution Approach 1:
The patent applies preliminary action by conducting preclinical studies and establishing the foundational scientific rationale before initiating full clinical trials. The development of standardized formulations and preliminary safety data provides a solid basis that accelerates subsequent clinical testing. By preparing the groundwork in advance, the time required for full clinical validation is reduced, while still ensuring reliable and robust clinical data is obtained.
Data Source
AI summary
Described is a cannabinoid-terpenoid solution (CTS) and method of treating a disease state or condition in animals other than humans via cannabinoid-terpenoid therapy. The CTS includes a unique combination of cannabinoids, terpenoids (terpenes), and a lipophilic carrier to allow safely and effectively treat the animal.